Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 48.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.96M |
| Shares Out | 46.55M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,094 |
| Open | 1.08 |
| Previous Close | 1.06 |
| Day's Range | 1.03 - 1.09 |
| 52-Week Range | 1.01 - 9.54 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 6.50 (+525.0%) |
| Earnings Date | May 5, 2022 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is 6.5, which is an increase of 525.00% from the latest price.
News
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
Company to host a webcast at 9:00am ET / 6:00am PT Company to host a webcast at 9:00am ET / 6:00am PT
Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now
Penny stocks insiders are buying right now. The post Best Penny Stocks To Watch In April?
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on M...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor C...
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in...
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Diseas...
Data Presented in Poster Presentation at American Society of Hematology Annual Meeting Data Presented in Poster Presentation at American Society of Hematology Annual Meeting
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Socie...
Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial res...
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Inform...
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of...
CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd.
Hot Penny Stocks to Buy This Week? 3 For Your October Watchlist
Making a list of penny stocks to buy in October? Check these three out The post Hot Penny Stocks to Buy This Week?
4 Buy-Ranked Stocks that Soared Over 20% in the Past Week
The market remains on its toes as investors digest the ton of information hitting us about now.
3 Biotech Stocks That Could Make You Filthy Rich
These three low-priced cancer stocks could be grossly undervalued.
Why Corvus Pharmaceuticals Stock Is Down Today
Profit taking appears to be in full effect today with this small-cap biotech.
Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial. The data from 40 patients suggested improvement in the primary and key secondary endpoints in patie...
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab t...
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options
Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.
Best Penny Stocks to Buy Right Now? 3 You Need to Know About
These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?
What's Going On With Corvus Pharmaceuticals Stock Today?
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for pati...
12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket
Corvus Pharmaceuticals (CRVS) stock is rising higher on heavy trading volume Friday despite a lack of news from the company. The post 12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (...
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...
Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021 Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021
Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...